A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen.
Mark Herzberg is a Professor of Clinical Haematology involved in clinical trials for patients with blood cancers, particularly lymphoma, leukaemia, and myeloma, in Australia and New Zealand.
Hodgkin lymphoma is a common cancer with varied symptoms, and treatment typically involves chemotherapy and sometimes radiation therapy.
Approximately 800 Australian patients are diagnosed with advanced stage Hodgkin lymphoma each year, with staging determined through imaging and blood tests.
Advanced stage Hodgkin lymphoma is treated with outpatient combination chemotherapy using two major regimens (ABVD and escalated BEACOPP) worldwide, with a global clinical trial involving nine cooperative groups in nine countries and 1500 patients.
The ALLG contributed 115 patients across 16 sites in Australia and New Zealand to a groundbreaking clinical trial.
A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen incorporating a new drug, Brentuximab Vedotin.
Patients experienced fewer side effects, such as anaemia, low platelet counts, peripheral neuropathy, and gonadal toxicity, while preserving fertility, with the modified BrECADD regimen in the treatment of advanced stage Hodgkin lymphoma.
Most patients with advanced stage Hodgkin lymphoma remained disease-free after three years of treatment, with a significant reduction in toxicity and shorter duration of treatment, allowing them to resume normal life and work sooner.
Australian Health Journal spoke with Professor Mark Hertzberg in his role in the ALLG HD10 Clinical Trial and as a former Chair of the Scientific Advisory Committee of the Australasian Leukaemia & Lymphoma Group (ALLG), an organisation involved in improving the treatments and lives of blood cancer patients.
-
Awareness campaigns and HCP Toolkits for thyroid health
In 2021, the Australian Thyroid Foundation released analysis to show, well over 1 million Australian are living with an undiagnosed thyroid disorder, including thyroid cancer, lower IQs, lifelong disability, and a causal or possible contributory factor – in the development of other neurological disorders such as ADHD and autism. Some of the challenges for diagnosis and treatment can be addressed by producing material for health care practitioners during patient presentations.
‘Recent statistics show well over 1 million Australians are living with an undiagnosed thyroid disorder, awareness and testing can prevent unwarranted outcomes for mothers and their babies’ says ATF CEO Beverley Garside OAM
The Australian Thyroid Foundation has lodged a Pre-Budget Submission for the Federal Budget 2024-25 to counter increasing misinformation on social media creating dietary deficiencies such as an increasing number of young women, who are planning pregnancy or already pregnant opting for plant based milks such almond, soy or oat milk coffee as an alternative to standard cow’s milk, which is a source of iodine and alternate milks do not include.
-
Jack Lancaster, Evolution Surgical
Continuing the Australian Health Journal, People In Health Care series is Jack Lancaster, the CEO of Evolution Surgical, an Australian owned company established in 2014, specialising in spinal fusion implants and custom instrumentation.
Jack talks about how the company works closely with surgeons to design custom solutions manufactured to surgical requirements, and ultimately, to the benefit of the Australia patient.
-
Outstanding Achievement
George FaithfullGeorge has been in the medical device industry in a variety of roles for over 35 years including Sales, Marketing, Business Development, General Management, R&D, Clinical, Regulatory and Government Affairs. He has worked for Stryker in Australia, USA and across Asia.
